📬 Breast Cancer Intelligence Digest — Week 2026-W40
Updated OlympiA six-year data and an accompanying Annals editorial dominate the week, alongside final IMpassion050 results, the FDA approval of imlunestrant plus abemaciclib, camizestrant's ctDNA-guided approval, the CompassHER2 pCR secondary analysis, and new ctDNA/MRD and cfDNA methylation early-detection debate.
⚡ TL;DR
🐦 Twitter / 🦋 Bluesky
- ESMO 2026 late-breaking abstracts drop, and breast oncologists publish competing top-10 lists — The ESMO 2026 late-breaking abstracts are out, with multiple trials in breast oncology to be presented in Madrid
- DBCG Skagen Trial 1 prospectively validates the ESTRO target volume consensus guideline in 2,963 patients — Prospective validation of the ESTRO target volume guideline was based on the phase III DBCG Skagen Trial 1 with 2,963 breast cancer patients
- Dana-Farber's updated consensus statement on first-line treatment for metastatic triple-negative breast cancer — Dana-Farber released an updated consensus statement on first-line treatment for metastatic triple-negative breast cancer
- NCI's BRIDGE AI tool predicts which breast cancers will achieve pathologic complete response to neoadjuvant chemotherapy — NCI-supported researchers developed an AI tool called BRIDGE that can predict which breast cancers will fully respond to chemotherapy given before surgery
- The TOP1-payload ADC loop: every new breast ADC trial excludes patients pretreated with a TOP1 ADC — Multiple ADCs with variable targets showing high efficacy in metastatic breast cancer share two features: a TOP1 payload, and only a handful or no TOP1-ADC pretreated patients in the trial
Full details below ↓
📄 What's Being Published
Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study. — Tutt Andrew et al., Clin Cancer Res
VIOLETTE (NCT03330847) randomized 273 patients 1:1:1 to olaparib, ceralasertib plus olaparib, or adavosertib plus olaparib as second-/third-line treatment across three molecular strata of PARP inhibitor-naive advanced TNBC; 114 received olaparib, 112 ceralasertib plus olaparib, and 47 adavosertib plus olaparib, with the adavosertib arm terminated early due to unacceptable toxicity. Median PFS with ceralasertib plus olaparib was 7.4, 3.9, and 3.6 months in the BRCA1/2m, non-BRCA1/2m HRRm, and non-HRRm strata, respectively, and did not differ significantly from olaparib (HR 1.02 [90% CI, 0.63–1.66], 0.54 [90% CI, 0.28–1.03], and 0.76 [90% CI, 0.50–1.14], respectively). In the non-HRRm group, ORR was significantly improved with ceralasertib plus olaparib (15.4%) versus olaparib (3.9%; OR, 4.45; 90% CI, 1.30–21.20; P = 0.0425), with no unexpected safety signals reported for either agent.
Clinical bottom line: Adding the ATR inhibitor ceralasertib to olaparib does not prolong PFS in any molecular stratum of PARP inhibitor-naive advanced TNBC, so despite a higher response rate in non-HRR-mutant disease this combination should not move into practice outside trials.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
ESMO 2026 late-breaking abstracts drop, and breast oncologists publish competing top-10 lists
The ESMO 2026 late-breaking abstracts are out, with multiple trials in breast oncology to be presented in Madrid. Clinicians circulated competing top-10 breast cancer abstract lists for ESMO 2026, with at least one sorted by day, session, and a "why it matters" context for the field. The central debate: which late-breaking breast abstract is most likely to change practice on the day it is presented.
Discussed by: @PTarantinoMD, @ErikaHamilton9, @dr_yakupergun
DBCG Skagen Trial 1 prospectively validates the ESTRO target volume consensus guideline in 2,963 patients
The phase III DBCG Skagen Trial 1, enrolling 2,963 breast cancer patients, provided prospective validation of the ESTRO target volume guideline; loco-regional recurrences occurred almost exclusively within the ESTRO CTVs, with no evidence supporting routine expansion of ESTRO-defined volumes. Separately, the 5-year analysis of the SUPREMO QOL substudy found that chest wall radiotherapy leads to a modest increase in local chest wall symptoms that improve over time, without significant effect on overall QOL and other domains. The question for radiation oncologists is whether any remaining justification exists for expanding target volumes beyond consensus contours given these convergent findings.
Discussed by: @to_be_elizabeth, @to_be_elizabeth, @subatomicdoc
Sources cited: PubMed
Dana-Farber's updated consensus statement on first-line treatment for metastatic triple-negative breast cancer
Dana-Farber released an updated consensus statement on first-line treatment for metastatic TNBC, prompting clinicians to articulate a broader concern: the drive to move every successful metastatic breast cancer therapy to the front line is stifling innovation, compounded by a "me too" mentality in drug development that crowds the same targets. Specialists argue that TNBC patients need effective treatment options after a TROP2-directed topoisomerase-1 ADC, noting that ADCs are "better chemo" but do not transform the tail of the OS curve. The unresolved question is what the evidence-based second-line option is after a TROP2-directed ADC, given the current absence of new targets and payloads.
Discussed by: @DFCI_BreastOnc, @drsarahsam, @DFCI_BreastOnc
NCI's BRIDGE AI tool predicts which breast cancers will achieve pathologic complete response to neoadjuvant chemotherapy
NCI-supported researchers developed an AI tool called BRIDGE that can predict which breast cancers will fully respond to chemotherapy given before surgery. Alongside this development, clinicians drew a distinction between the complementary roles of pCR and residual cancer burden: pCR reports response, RCB refines prognosis, and not all non-pCR outcomes are equivalent — RCB guides escalation decisions. The open question is whether a pre-treatment pCR prediction should be used to de-escalate neoadjuvant chemotherapy or only to select patients for escalation once residual cancer burden is known.
Discussed by: @JaniceTNBCmets, @ChandrakanthMv
The TOP1-payload ADC loop: every new breast ADC trial excludes patients pretreated with a TOP1 ADC
A pointed observation circulated this week: multiple ADCs with variable targets showing high efficacy in metastatic breast cancer share two consistent features — a TOP1 payload and only a handful or no TOP1-ADC pretreated patients enrolled in the trial. A recent review on antibody-drug conjugates in breast cancer in the first-line and curative setting was shared alongside the debate, and ADC sequencing and whether ADC target expression matters were flagged as unresolved topics at dedicated sessions. The structural question is whether regulators and cooperative groups should require new TOP1-payload ADC trials to enroll patients previously treated with a TOP1 ADC before those agents are approved.
Discussed by: @JaniceTNBCmets, @JaniceTNBCmets, @DFCI_BreastOnc
Sources cited: PubMed
A JCO piece on carboplatin dosing reopens the case for carboplatin-sparing regimens in HER2-positive early breast cancer
A JCO piece arguing that adequate calculation of carboplatin dosage remains controversial after decades of usage added weight to the case for carboplatin-sparing approaches in HER2-positive early breast cancer, where recent data suggest a marginal therapeutic role for the drug. In the phase III Neo-Healer trial, anbenitamab plus HB1801 chemotherapy improved pathologic complete response across key subgroups of ERBB2-positive breast cancer — including HR-positive and HR-negative disease — with or without carboplatin, adding to the debate. Clinicians are now asking whether uncertain AUC-based dosing and marginal incremental benefit justify dropping carboplatin from neoadjuvant HER2-positive regimens outright rather than continuing to dose by convention.
Discussed by: @PTarantinoMD, @ASCOPost, @Dr_Oncologista
Sources cited: Reply to: “Creatinine Assay Methods and Carboplatin Dosing Transparency in the neoCARHP T… (Journal of Clinical Oncology, 2026) · PubMed · The ASCO Post
IMpassion050 final analysis: atezolizumab adds nothing to neoadjuvant HER2-directed therapy, with an unexplained DFS signal in PD-L1-negative disease
The final IMpassion050 analysis, at approximately 44 months of follow-up, confirmed that adding atezolizumab to HER2-directed therapy did not significantly improve EFS (HR 0.90) or DFS (HR 0.71) in high-risk HER2-positive early breast cancer; three-year EFS was 91.4% versus 89.0% (HR 0.90; 95% CI, 0.50–1.59). A DFS signal in PD-L1-negative disease (HR 0.44) attracted attention but is based on few events and wide confidence intervals. Clinicians are divided on whether this signal justifies any further checkpoint inhibitor testing in HER2-positive early breast cancer, or whether the hypothesis is effectively closed given the event counts.
Discussed by: @dr_yakupergun, @Dr_Oncologista
Sources cited: ESMO Open
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
RT @DrRishabhOnco: 🧬 OlympiA: 1 year of olaparib, survival benefit still holding at 6 years.
Updated phase III OlympiA data in germline BRCA1/2-mutated, high-risk HER2-negative early breast cancer show sustained benefit after adjuvant olaparib.
📍 Median follow-up: 6.1 years
📈 IDFS: 79.6% vs 70.3%
➡️ HR 0.65
✅ +9.4% absolute benefit
🌍 DDFS: 83.5% vs 75.7%
➡️ HR 0.65
✅ +7.8% absolute benefit
❤️ OS: 87.5% vs 83.2%
➡️ HR 0.72
✅ +4.4% absolute survival benefit
🔎 Benefit remained consistent across key subgroups including TNBC, HR+/HER2− disease, BRCA1, BRCA2, prior platinum, and adjuvant vs neoadjuvant chemotherapy.
🛡️ Importantly, no late MDS/AML safety signal emerged: 0.4% vs 0.7% with placebo.
💡 Clinical takeaway:
A finite 1-year course of adjuvant olaparib continues to deliver meaningful long-term recurrence and survival benefit in appropriately selected gBRCA1/2 high-risk HER2-negative early breast cancer.
@ASCO @OncoAlert
#BreastCancer #BRCA #Olaparib #OlympiA
🔖 10 ❤️ 30 🔁 14 👁 1,569
OncoAlert @OncoAlert
What does 6 years of follow-up tell us about 1 year of adjuvant olaparib? The OlympiA trial continues to show meaningful improvements in disease-free and overall survival in high-risk, 🧬HER2-negative early #BreastCancer
In this #WeekinOncology by OncoAlert, we have our colleague Dr. Gaia Griguolo 🇮🇹 discussing the latest update of OlympiA
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Link to Article
https://t.co/JPDHcD3m8L
The OlympiA trial shows that one year of adjuvant olaparib provides sustained benefits in patients with high-risk, HER2-negative early breast cancer and germline BRCA1/2 pathogenic variants.
➡️At 6.1 years, olaparib improved invasive disease-free, distant disease-free, and overall survival, with a 4.4% absolute six-year OS benefit.
➡️Benefits were consistent across subgroups. Toxicity remained acceptable, with no increased risk of MDS or AML, supporting continued adjuvant use.
@LoiblSibylle, @MichaelGnant, @drkellyphillips, @ZoppoliGabriele
@hoperugo, @matteolambe, @ErikaHamilton9, @DrSGraff, @aftimosp, @BianchiniGP, @raalbany, @jamecancerdoc, @Icro_Meattini, @stolaney1, @maryam_lustberg, @LoiSher, @stage4kelly, @JaniceTNBCmets, @TanjaSpanic, @christeeny513, @stage4kelly, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @UOzkerim, @DrVilmaPBarcia, @nataliagandur
🔖 1 ❤️ 14 🔁 7 👁 1,329
Janice Cowden @JaniceTNBCmets
RT @ErikaHamilton9: 10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026.
Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression.
#clinicaltrials win! Patients win! https://t.co/0rcRciQ4rE
🔖 38 ❤️ 88 🔁 42 👁 12,612
Oncology Brothers @OncBrothers
RT @ErikaHamilton9: 10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026.
Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression.
#clinicaltrials win! Patients win! https://t.co/0rcRciQ4rE
🔖 38 ❤️ 88 🔁 42 👁 12,612
Kazuki Nozawa, MD @kazuki_nozawa
RT @ErikaHamilton9: 10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026.
Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression.
#clinicaltrials win! Patients win! https://t.co/0rcRciQ4rE
🔖 38 ❤️ 88 🔁 42 👁 12,612
Sara Tolaney @stolaney1
RT @ErikaHamilton9: 10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026.
Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression.
#clinicaltrials win! Patients win! https://t.co/0rcRciQ4rE
🔖 38 ❤️ 88 🔁 42 👁 12,612
Sara Tolaney @stolaney1
RT @TheCancerLetter: FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
https://t.co/9uSxViOGRn
🔖 0 ❤️ 2 🔁 1 👁 857
MV Chandrakanth @ChandrakanthMv
SERENA-6 — my running notes 📝
Inspired by an excellent Oncology Brothers video discussion with Dr Erica Mayer on translating SERENA-6 into everyday practice.
🎥 Full discussion:
https://t.co/RDT1cBSEnh
• Who & when to test? After ≥6 months of 1L AI + CDK4/6i, serial ctDNA monitoring can detect emerging ESR1m before radiological progression.
• Does switching early matter? AI → camizestrant while continuing the same CDK4/6i improved PFS: 9.2 → 16.8 months | HR 0.45
• Does the benefit persist? PFS2: 19.1 → 25.7 months | HR 0.63, with chemotherapy/ADC-free survival also prolonged.
• Co-mutations? PFS benefit was preserved with PIK3CA and TP53.
• What happens biologically? ESR1 mutant allele frequency fell profoundly within weeks after switching to camizestrant.
• Which CDK4/6i? SERENA-6 included palbociclib, ribociclib and abemaciclib—the same CDK4/6i was continued.
• The bigger question: Do we always wait for the scan to progress—or can we detect endocrine resistance molecularly and intercept it earlier?
My running notes & takeaways — not a transcript.
#SERENA6 #Camizestrant #ESR1 #ctDNA #BreastCancer #PrecisionOncology #MedicalOncology #MVOnco
🔖 48 ❤️ 74 🔁 27 👁 3,892
Sara Tolaney @stolaney1
RT @ChandrakanthMv: SERENA-6 — my running notes 📝
Inspired by an excellent Oncology Brothers video discussion with Dr Erica Mayer on translating SERENA-6 into everyday practice.
🎥 Full discussion:
https://t.co/RDT1cBSEnh
• Who & when to test? After ≥6 months of 1L AI + CDK4/6i, serial ctDNA monitoring can detect emerging ESR1m before radiological progression.
• Does switching early matter? AI → camizestrant while continuing the same CDK4/6i improved PFS: 9.2 → 16.8 months | HR 0.45
• Does the benefit persist? PFS2: 19.1 → 25.7 months | HR 0.63, with chemotherapy/ADC-free survival also prolonged.
• Co-mutations? PFS benefit was preserved with PIK3CA and TP53.
• What happens biologically? ESR1 mutant allele frequency fell profoundly within weeks after switching to camizestrant.
• Which CDK4/6i? SERENA-6 included palbociclib, ribociclib and abemaciclib—the same CDK4/6i was continued.
• The bigger question: Do we always wait for the scan to progress—or can we detect endocrine resistance molecularly and intercept it earlier?
My running notes & takeaways — not a transcript.
#SERENA6 #Camizestrant #ESR1 #ctDNA #BreastCancer #PrecisionOncology #MedicalOncology #MVOnco
🔖 48 ❤️ 74 🔁 27 👁 3,892
OncLive.com @OncLive
WATCH: @elmayermd, of @DanaFarber and @harvardmed, highlights the @FDA approval of camizestrant plus a CDK4/6 inhibitor for HR+, HER2–, advanced/metastatic breast cancer that acquires an ESR1 mutation. #bcsm #oncology
Read our coverage of the approval: https://t.co/lvlywoHXtU https://t.co/fNpuc5TwT0
🔖 0 ❤️ 7 🔁 3 👁 1,141
OncLive.com @OncLive
WATCH 🎥: @elmayermd, of @DanaFarber and @harvardmed, discusses the @FDA approval of camizestrant for emergent ESR1-mutated breast cancer and the clinical role of the ctDNA-guided switch paradigm introduced by SERENA-6. #bcsm #oncology
Full video ➡️: https://t.co/31Z4iOjnVX
🔖 1 ❤️ 7 🔁 2 👁 845
OncLive.com @OncLive
ICYMI 💥: The @FDA made their decision on SERENA-6 by approving camizestrant plus a CDK4/6 inhibitor for emergent ESR1-mutated HR+, HER2–avanced breast cancer.
Catch up here :📈 https://t.co/YsAPYnVeGv
#bcsm #Oncology
🔖 0 ❤️ 5 🔁 0 👁 1,252
Memorial Sloan Kettering Cancer Center @mskcancercenter.bsky.social
🚨 The FDA has approved imlunestrant (Inluriyo™) in combination with abemaciclib (Verzenio®) for patients with ER-positive, HER2-negative advanced #breastcancer with an ESR1 gene mutation who were previously treated with hormone therapy.
🔖 0 ❤️ 2 🔁 1 👁 0
Cancer Survivors Club 📙 @thecancersurvivorsclub.com
Another treatment option for advanced breast cancer. The FDA has approved imlunestrant plus abemaciclib for certain patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic disease.
www.fda.gov/drugs/resour...
#BreastCancer #CancerTreatment #TCSC
🔖 0 ❤️ 0 🔁 0 👁 0
SABCS @SABCSSanAntonio
Today, @US_FDA approved the targeted therapy datopotamab deruxtecan-dlnk for adults with unresectable or metastatic TNBC who are not candidates for certain checkpoint inhibitors. The approval was based on data presented at #SABCS25. Learn more:
https://t.co/2amP9uOQz5 https://t.co/chUv3eVzuk
🔖 0 ❤️ 5 🔁 1 👁 597
🧪 Newly Recruiting Trials
1 trial (1 phase I) opened this week, testing HTR2 T cells
Phase 1 · Baylor College of Medicine · HTR2 T cells · Texas · CT.gov ↗
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.
☕ Not funded by anyone — no sponsors, no pharma. Buy me a coffee if it's useful.